Showing 7451-7460 of 8879 results for "".
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- Dupixent Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe ADhttps://practicaldermatology.com/news/dupixent-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-ad/2460619/The European Commission (EC) has given its nod to Dupixent (dupilumab) for children 6 to 11 with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients. "As the parent
- Merz Aesthetics Calls for Entries for First-Ever Innovation Forumhttps://practicaldermatology.com/news/merz-aesthetics-calls-for-entries-for-first-ever-innovation-forum/2460618/Merz Aesthetics is launching its first-ever Innovation Forum with a call for abstract submissions seeking the most creative and inventive medical aesthetics abstracts from the next generation of researchers and healthcare professionals. The author of the winning abstrac
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond n
- Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hourshttps://practicaldermatology.com/news/telemedicine-slashes-dermatology-consult-time-from-84-days-to-5-hours/2460609/When patients’ primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours, finds a new study from researchers in the Perelman School of Medicine at the Unive
- Avita Therapeutics, Houston Methodist Research Institute to Develop New Ways to Rejuvenate Aging Skinhttps://practicaldermatology.com/news/avita-therapeutics-houston-methodist-research-institute-to-develop-new-ways-to-rejuvenate-aging-skin/2460608/Avita Therapeutics’ is partnering with Houston Methodist Research Institute (HMRI) to identify novel approaches to reverse skin aging and rejuvenate skin with the potential for broader applicability such as scar revision and wound healing. The project seeks to establish
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve